Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Toxicities in Early-Stage Invasive Breast Cancer

Cancer; ePub 2017 Jan 24; Friese, Harrison, et al

Substantial treatment-associated toxicities and related burden were reported by women with early-stage breast cancer, a recent study found. Between 2013 and 2014, the iCanCare study surveyed 1,945 women residing in Los Angeles County and Georgia with early-stage, invasive breast cancer to assess the frequency and severity of toxicities. Researchers found:

  • 866 (45%) women reported at least 1 toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital.
  • Receipt of chemotherapy (OR, 2.2), receipt of both chemotherapy and radiotherapy (OR, 1.3), and Latina ethnicity (OR vs whites, 1.3) were associated with reported higher toxicity severity.
  • Bilateral mastectomy recipients reported a nonsignificant increase in at least 1 severe/very severe toxicity (OR, 1.2).

Citation:

Friese CR, Harrison JM, Janz NK, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. [Published online ahead of print January 24, 2017]. Cancer. doi:10.1002/cncr.30547.